K. Allers, G. Hutter, J. Hofmann, C. Loddenkemper, K. Rieger et al., Evidence for the cure of HIV infection by CCR5??32/??32 stem cell transplantation, Blood, vol.117, issue.10, pp.2791-2799, 2011.
DOI : 10.1182/blood-2010-09-309591

A. Allouch, A. David, S. M. Amie, H. Lahouassa, L. Chartier et al., p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway, Proceedings of the National Academy of Sciences, vol.16, issue.13, pp.3997-4006
DOI : 10.1089/08892220050117014
URL : https://hal.archives-ouvertes.fr/pasteur-01420537

J. R. Almeida, D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce et al., T cells is reflected by their avidity, polyfunctionality, and clonal turnover, The Journal of Experimental Medicine, vol.93, issue.10, pp.2473-2485, 2007.
DOI : 10.1016/S0022-1759(02)00195-3
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118466

P. K. Amancha, J. J. Hong, K. Rogers, A. A. Ansari, and F. Villinger, In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit, The Journal of Immunology, vol.191, issue.12, pp.6060-6070, 2013.
DOI : 10.4049/jimmunol.1302044

J. Ananworanich, A. Schuetz, C. Vandergeeten, I. Sereti, M. De-souza et al., Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection, PLoS ONE, vol.355, issue.3, p.33948, 2012.
DOI : 10.1371/journal.pone.0033948.t002

N. M. Archin, M. Cheema, D. Parker, A. Wiegand, R. J. Bosch et al., Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection, PLoS ONE, vol.5, issue.2, p.9390, 2010.
DOI : 10.1371/journal.pone.0009390.t001
URL : http://doi.org/10.1371/journal.pone.0009390

N. M. Archin, A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc et al., Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy, Nature, vol.15, issue.7408, pp.482-485, 2012.
DOI : 10.1038/sj.leu.2404221

N. M. Archin, N. K. Vaidya, J. D. Kuruc, A. L. Liberty, A. Wiegand et al., Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection, Proceedings of the National Academy of Sciences, vol.366, issue.9485, pp.9523-9528, 2012.
DOI : 10.1016/S0140-6736(05)67098-5

D. M. Asmuth, R. L. Murphy, S. L. Rosenkranz, J. J. Lertora, S. Kottilil et al., Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa???2a in HIV???1???Monoinfected Participants: A Phase II Clinical Trial, The Journal of Infectious Diseases, vol.201, issue.11, pp.1686-1696, 2010.
DOI : 10.1086/652420

V. Avettand-fenoel, N. Mahlaoui, M. L. Chaix, C. Milliancourt, M. Burgard et al., Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART, AIDS, vol.21, issue.6, pp.776-777, 2007.
DOI : 10.1097/QAD.0b013e3280b01836

L. Azzoni, A. S. Foulkes, E. Papasavvas, A. M. Mexas, K. M. Lynn et al., Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration, The Journal of Infectious Diseases, vol.207, issue.2, pp.213-222, 2013.
DOI : 10.1093/infdis/jis663

C. Banerjee, N. Archin, D. Michaels, A. C. Belkina, G. V. Denis et al., BET bromodomain inhibition as a novel strategy for reactivation of HIV-1, Journal of Leukocyte Biology, vol.92, issue.6, pp.1147-1154, 2012.
DOI : 10.1189/jlb.0312165

D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira et al., Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys, Nature, vol.86, pp.224-228
DOI : 10.1038/nature12744

F. Barre-sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret et al., Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), 1983.

G. J. Besson, D. Mcmahon, F. Maldarelli, and J. W. Mellors, Short-Course Raltegravir Intensification Does Not Increase 2 Long Terminal Repeat Episomal HIV-1 DNA in Patients on Effective Antiretroviral Therapy, Clinical Infectious Diseases, vol.54, issue.3, pp.451-453, 2012.
DOI : 10.1093/cid/cir721

D. A. Bisgrove, T. Mahmoudi, P. Henklein, and E. Verdin, Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription, Proceedings of the National Academy of Sciences, vol.11, issue.5, pp.13690-13695, 2007.
DOI : 10.1093/nar/11.5.1475
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959443

M. T. Bloch, D. E. Smith, D. Quan, J. M. Kaldor, J. J. Zaunders et al., The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.2, pp.192-202, 2006.
DOI : 10.1097/01.qai.0000219779.50668.e6

F. Boue, J. Reynes, C. Rouzioux, D. Emilie, F. Souala et al., Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial, AIDS, vol.25, issue.1, pp.115-118, 2011.
DOI : 10.1097/QAD.0b013e328340a1e7

M. J. Buzon, M. Massanella, J. M. Llibre, A. Esteve, V. Dahl et al., HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects, Nature Medicine, vol.77, issue.4, pp.460-465, 2010.
DOI : 10.1038/nm.2111

M. Carrington, G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov et al., HLA and HIV-1: Heterozygote Advantage and B*35-Cw*04 Disadvantage, Science, vol.283, issue.5408, pp.1748-1752, 1999.
DOI : 10.1126/science.283.5408.1748

A. Chamberland, M. Sylla, M. R. Boulassel, J. G. Baril, P. Cote et al., Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection, International Journal of STD & AIDS, vol.71, issue.3, pp.146-150, 2011.
DOI : 10.1093/molbev/msm092

N. Chomont, M. El-far, P. Ancuta, L. Trautmann, F. A. Procopio et al., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation, Nature Medicine, vol.45, issue.8, pp.893-900, 2009.
DOI : 10.1038/nm.1972
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859814

T. W. Chun, J. S. Justement, D. Murray, C. W. Hallahan, J. Maenza et al., Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication, AIDS, vol.24, issue.18, pp.2803-2808, 2010.
DOI : 10.1097/QAD.0b013e328340a239

T. W. Chun, L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican et al., Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy, Proceedings of the National Academy of Sciences, vol.278, issue.5341, pp.13193-13197, 1997.
DOI : 10.1126/science.278.5341.1291

A. R. Cillo, A. Krishnan, R. T. Mitsuyasu, D. K. Mcmahon, S. Li et al., Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.4, pp.438-441, 2013.
DOI : 10.1097/QAI.0b013e31828e6163
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699958

D. B. Clifford and B. M. Ances, HIV-associated neurocognitive disorder, The Lancet Infectious Diseases, vol.13, issue.11, pp.976-986, 2013.
DOI : 10.1016/S1473-3099(13)70269-X

M. S. Cohen, Y. Q. Chen, M. Mccauley, T. Gamble, M. C. Hosseinipour et al., Prevention of HIV-1 Infection with Early Antiretroviral Therapy, New England Journal of Medicine, vol.365, issue.6, pp.493-505, 2011.
DOI : 10.1056/NEJMoa1105243

L. Contu, L. Nasa, G. Arras, M. Pizzati, A. Vacca et al., Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS, Bone Marrow Transplant, vol.12, pp.669-671, 1993.

D. A. Cooper, J. Heera, J. Goodrich, M. Tawadrous, M. Saag et al., Maraviroc versus Efavirenz, Both in Combination with Zidovudine???Lamivudine, for the Treatment of Antiretroviral???Naive Subjects with CCR5???Tropic HIV???1 Infection, The Journal of Infectious Diseases, vol.201, issue.6, pp.803-813, 2010.
DOI : 10.1086/650697

P. Corbeau and J. Reynes, Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection, Blood, vol.117, issue.21, pp.5582-5590, 2011.
DOI : 10.1182/blood-2010-12-322453

L. Cuzin, S. Trabelsi, P. Delobel, C. Barbuat, J. Reynes et al., Maraviroc Intensification of Stable Antiviral Therapy in HIV-1???Infected Patients With Poor Immune Restoration, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.5, pp.557-564, 2012.
DOI : 10.1097/QAI.0b013e318273015f
URL : https://hal.archives-ouvertes.fr/hal-00767144

D. Orso, I. Frankel, and A. D. , RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation, Nature Structural & Molecular Biology, vol.277, issue.7, pp.815-821, 2010.
DOI : 10.1038/nsmb.1827

V. Dahl, E. Lee, J. Peterson, S. S. Spudich, I. Leppla et al., Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy, Journal of Infectious Diseases, vol.204, issue.12, pp.1936-1945, 2011.
DOI : 10.1093/infdis/jir667

M. Dean, M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith et al., Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene, Science, vol.273, issue.5283, pp.1856-1862, 1996.
DOI : 10.1126/science.273.5283.1856

S. G. Deeks, S. R. Lewin, and D. V. Havlir, The end of AIDS: HIV infection as a chronic disease, The Lancet, vol.382, issue.9903, pp.1525-1533, 2013.
DOI : 10.1016/S0140-6736(13)61809-7

D. Benedetto, F. , D. Sandro, S. De-ruvo, N. Montalti et al., First Report on a Series of HIV Patients Undergoing Rapamycin Monotherapy After Liver Transplantation, Transplantation, vol.89, issue.6, pp.733-738, 2010.
DOI : 10.1097/TP.0b013e3181c7dcc0

C. A. Didigu, C. B. Wilen, J. Wang, J. Duong, A. J. Secreto et al., Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection, Blood, vol.123, issue.1, pp.61-69, 2014.
DOI : 10.1182/blood-2013-08-521229

J. B. Dinoso, S. Y. Kim, A. M. Wiegand, S. E. Palmer, S. J. Gange et al., Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy, Proceedings of the National Academy of Sciences, vol.74, issue.3, pp.9403-9408, 2009.
DOI : 10.1016/j.cmpb.2003.08.004

M. Donia, J. A. Mccubrey, K. Bendtzen, and F. Nicoletti, Potential use of rapamycin in HIV infection, British Journal of Clinical Pharmacology, vol.5, issue.B, pp.784-793, 2010.
DOI : 10.1111/j.1365-2125.2010.03735.x

T. Doyle and A. M. Geretti, Low-level viraemia on HAART, Current Opinion in Infectious Diseases, vol.25, issue.1, pp.17-25, 2012.
DOI : 10.1097/QCO.0b013e32834ef5d9

F. Guerrero, M. L. Rivas, P. Molina, M. Garcia, R. De-gorgolas et al., Long-Term Follow-Up of Asymptomatic HIV-Infected Patients Who Discontinued Antiretroviral Therapy, Clinical Infectious Diseases, vol.41, issue.3, pp.390-394, 2005.
DOI : 10.1086/431487

S. Fidler, K. Porter, F. Ewings, J. Frater, G. Ramjee et al., Short-course antiretroviral therapy in primary HIV infection, N Engl J Med, vol.368, pp.207-217, 2013.

A. C. Finnefrock, A. Tang, F. Li, D. C. Freed, M. Feng et al., PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination, The Journal of Immunology, vol.182, issue.2, pp.980-987, 2009.
DOI : 10.4049/jimmunol.182.2.980

C. V. Fletcher, K. Staskus, S. W. Wietgrefe, M. Rothenberger, C. Reilly et al., Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues, Proceedings of the National Academy of Sciences, vol.111, issue.6, pp.2307-2312, 2014.
DOI : 10.1086/315178

J. Gabarre, A. G. Marcelin, N. Azar, S. Choquet, V. Levy et al., High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease, Haematologica, vol.89, pp.1100-1108, 2004.

R. T. Gandhi, R. W. Coombs, E. S. Chan, R. J. Bosch, L. Zheng et al., No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1???Infected Patients Receiving Antiretroviral Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.59, issue.3, pp.229-235, 2012.
DOI : 10.1097/QAI.0b013e31823fd1f2

R. T. Gandhi, L. Zheng, R. J. Bosch, E. S. Chan, D. M. Margolis et al., The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial, PLoS Med, vol.7, 2010.

S. Gianella, V. Von-wyl, M. Fischer, B. Niederoest, M. Battegay et al., Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA, Antiviral Therapy, vol.16, issue.4, 2011.
DOI : 10.3851/IMP1776

K. B. Glaser, M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich et al., Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines, Mol Cancer Ther, vol.2, pp.151-163, 2003.

C. Goujard, D. Emilie, C. Roussillon, V. Godot, C. Rouzioux et al., Continuous versus intermittent treatment strategies during primary HIV-1 infection, AIDS, vol.26, issue.15, pp.1895-1905, 2012.
DOI : 10.1097/QAD.0b013e32835844d9
URL : https://hal.archives-ouvertes.fr/hal-00875175

C. Goujard, I. Girault, C. Rouzioux, C. Lecuroux, C. Deveau et al., HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy, Antiviral Therapy, vol.17, issue.6, pp.1001-1009, 2012.
DOI : 10.3851/IMP2273

M. Guadalupe, S. Sankaran, M. D. George, E. Reay, D. Verhoeven et al., Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection, Journal of Virology, vol.80, issue.16, pp.8236-8247, 2006.
DOI : 10.1128/JVI.00120-06

E. Guan, J. Wang, G. Roderiquez, and M. A. Norcross, Natural Truncation of the Chemokine MIP-1beta /CCL4 Affects Receptor Specificity but Not Anti-HIV-1 Activity, Journal of Biological Chemistry, vol.277, issue.35, pp.32348-32352, 2002.
DOI : 10.1074/jbc.M203077200

C. Gutierrez, L. Diaz, A. Vallejo, B. Hernandez-novoa, M. Abad et al., Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected, PLoS ONE, vol.116, issue.12, 2011.
DOI : 10.1371/journal.pone.0027864.s002

C. Hamimi, G. Pancino, F. Barre-sinoussi, and A. Saez-cirion, Will it be possible to live without antiretroviral therapy?, Current Opinion in HIV and AIDS, vol.8, issue.3, pp.196-203, 2013.
DOI : 10.1097/COH.0b013e32835f94d5
URL : https://hal.archives-ouvertes.fr/pasteur-01420531

S. G. Hansen, M. Piatak, . Jr, A. B. Ventura, C. M. Hughes et al., Immune clearance of highly pathogenic SIV infection, Nature, vol.69, issue.7469, pp.100-104, 2013.
DOI : 10.1038/nature12519
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849456

S. G. Hansen, J. B. Sacha, C. M. Hughes, J. C. Ford, B. J. Burwitz et al., Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms, Science, vol.82, issue.2, 1237874.
DOI : 10.1128/JVI.01816-07
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816976

H. Hatano, Immune activation and HIV persistence, Current Opinion in HIV and AIDS, vol.8, issue.3, pp.211-216, 2013.
DOI : 10.1097/COH.0b013e32835f9788
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041488

H. Hatano, T. L. Hayes, V. Dahl, E. Sinclair, T. H. Lee et al., A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response, Journal of Infectious Diseases, vol.203, issue.7, pp.960-968, 2011.
DOI : 10.1093/infdis/jiq138

H. Hatano, M. C. Strain, R. Scherzer, P. Bacchetti, D. Wentworth et al., Increase in 2???Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial, The Journal of Infectious Diseases, vol.208, issue.9, pp.1436-1442, 2013.
DOI : 10.1093/infdis/jit453

D. V. Havlir, M. C. Strain, M. Clerici, C. Ignacio, D. Trabattoni et al., Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years, Journal of Virology, vol.77, issue.20, pp.11212-11219, 2003.
DOI : 10.1128/JVI.77.20.11212-11219.2003

F. M. Hecht, L. Wang, A. Collier, S. Little, M. Markowitz et al., A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection, The Journal of Infectious Diseases, vol.194, issue.6, pp.725-733, 2006.
DOI : 10.1086/506616

T. J. Henrich, Z. Hu, J. Z. Li, G. Sciaranghella, M. P. Busch et al., Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation, Journal of Infectious Diseases, vol.207, issue.11, pp.1694-1702, 2013.
DOI : 10.1093/infdis/jit086

Y. C. Ho, L. Shan, N. N. Hosmane, J. Wang, S. B. Laskey et al., Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure, Cell, vol.155, issue.3, pp.540-551, 2013.
DOI : 10.1016/j.cell.2013.09.020

L. Hocqueloux, T. Prazuck, V. Avettand-fenoel, A. Lafeuillade, B. Cardon et al., Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection, AIDS, vol.24, issue.10, pp.1598-1601, 2010.
DOI : 10.1097/QAD.0b013e32833b61ba

H. K. Holland, R. Saral, J. J. Rossi, A. D. Donnenberg, W. H. Burns et al., Allogeneic Bone Marrow Transplantation, Zidovudine, and Human Immunodeficiency Virus Type 1 (HIV-I) Infection, Annals of Internal Medicine, vol.111, issue.12, pp.973-981, 1989.
DOI : 10.7326/0003-4819-111-12-973

N. Holt, J. Wang, K. Kim, G. Friedman, X. Wang et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo, Nature Biotechnology, vol.11, issue.8, pp.839-847, 2010.
DOI : 10.1038/nbt.1663

K. Huber, G. Doyon, J. Plaks, E. Fyne, J. W. Mellors et al., Inhibitors of Histone Deacetylases: CORRELATION BETWEEN ISOFORM SPECIFICITY AND REACTIVATION OF HIV TYPE 1 (HIV-1) FROM LATENTLY INFECTED CELLS, Journal of Biological Chemistry, vol.286, issue.25, pp.22211-22218, 2011.
DOI : 10.1074/jbc.M110.180224

P. W. Hunt, J. Brenchley, E. Sinclair, J. M. Mccune, M. Roland et al., T Cell Count in HIV???Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy, The Journal of Infectious Diseases, vol.197, issue.1, pp.126-133, 2008.
DOI : 10.1086/524143

P. W. Hunt, N. S. Shulman, T. L. Hayes, V. Dahl, M. Somsouk et al., The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial, Blood, vol.121, issue.23, pp.4635-4646, 2013.
DOI : 10.1182/blood-2012-06-436345

G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig et al., Delta32/Delta32 Stem-Cell Transplantation, New England Journal of Medicine, vol.360, issue.7, pp.692-698, 2009.
DOI : 10.1056/NEJMoa0802905

S. Itescu, U. Mathur-wagh, M. L. Skovron, L. J. Brancato, M. Marmor et al., HLA-B35 is associated with accelerated progression to AIDS, J Acquir Immune Defic Syndr, vol.5, pp.37-45, 1992.

D. E. Kaufmann, P. M. Bailey, J. Sidney, B. Wagner, P. J. Norris et al., Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides, Journal of Virology, vol.78, issue.9, 2004.
DOI : 10.1128/JVI.78.9.4463-4477.2004

H. P. Kiem, K. R. Jerome, S. G. Deeks, and J. M. Mccune, Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease, Cell Stem Cell, vol.10, issue.2, pp.137-147, 2012.
DOI : 10.1016/j.stem.2011.12.015
URL : http://doi.org/10.1016/j.stem.2011.12.015

A. Koc, L. J. Wheeler, C. K. Mathews, and G. F. Merrill, Hydroxyurea Arrests DNA Replication by a Mechanism That Preserves Basal dNTP Pools, Journal of Biological Chemistry, vol.279, issue.1, pp.223-230, 2004.
DOI : 10.1074/jbc.M303952200

J. E. Lake and J. S. Currier, Metabolic disease in HIV infection, The Lancet Infectious Diseases, vol.13, issue.11, pp.964-975, 2013.
DOI : 10.1016/S1473-3099(13)70271-8

G. Lehrman, I. B. Hogue, S. Palmer, C. Jennings, C. A. Spina et al., Depletion of latent HIV-1 infection in vivo: a proof-of-concept study, The Lancet, vol.366, issue.9485, pp.549-555, 2005.
DOI : 10.1016/S0140-6736(05)67098-5

A. Leone, L. J. Picker, and D. L. Sodora, IL-2, IL-7 and IL-15 as Immuno-Modulators During SIV/HIV Vaccination and Treatment, Current HIV Research, vol.7, issue.1, pp.83-90, 2009.
DOI : 10.2174/157016209787048519

Y. Levy, C. Lacabaratz, L. Weiss, J. P. Viard, C. Goujard et al., Enhanced T cell recovery in HIV-1???infected adults through IL-7 treatment, Journal of Clinical Investigation, vol.119, pp.997-1007, 2009.
DOI : 10.1172/JCI38052
URL : https://hal.archives-ouvertes.fr/inserm-00484803

Y. Levy, I. Sereti, G. Tambussi, J. P. Routy, J. D. Lelievre et al., Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study, Clinical Infectious Diseases, vol.55, issue.2, pp.291-300, 2012.
DOI : 10.1093/cid/cis383

M. G. Lewis, S. Dafonseca, N. Chomont, A. T. Palamara, M. Tardugno et al., Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension, AIDS, vol.25, issue.11, pp.1347-1356, 2011.
DOI : 10.1097/QAD.0b013e328347bd77

Z. Li, J. Guo, Y. Wu, and Q. Zhou, The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation, Nucleic Acids Research, vol.41, issue.1, pp.277-287, 2013.
DOI : 10.1093/nar/gks976

A. S. Liovat, M. A. Rey-cuille, C. Lecuroux, B. Jacquelin, I. Girault et al., Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection, PLoS ONE, vol.7, issue.10, p.46143, 2012.
DOI : 10.1371/journal.pone.0046143.s007

J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco et al., Control of HIV despite the Discontinuation of Antiretroviral Therapy, New England Journal of Medicine, vol.340, issue.21, pp.1683-1684, 1999.
DOI : 10.1056/NEJM199905273402114

S. Lodi, L. Meyer, A. D. Kelleher, M. Rosinska, J. Ghosn et al., Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion, Archives of Internal Medicine, vol.172, issue.16, pp.1252-1255, 2012.
DOI : 10.1001/archinternmed.2012.2719

F. Lori, D. De-forni, E. Katabira, D. Baev, R. Maserati et al., VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics, PLoS ONE, vol.7, issue.10, p.47485, 2012.
DOI : 10.1371/journal.pone.0047485.s003

F. Lori, A. Foli, A. Groff, L. Lova, L. Whitman et al., Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (???virostatic???) mechanisms, AIDS, vol.19, issue.11, pp.1173-1181, 2005.
DOI : 10.1097/01.aids.0000176217.02743.d1

F. Lori and J. Lisziewicz, Rationale for the Use of Hydroxyurea as an Anti-Human Immunodeficiency Virus Drug, Clinical Infectious Diseases, vol.30, issue.Supplement 2, pp.193-197, 2000.
DOI : 10.1086/313851

G. Lucotte, Frequencies of 32 base pair deletion of the (??32) allele of the CCR5 HIV-1 co-receptor gene in Caucasians: a comparative analysis, Infection, Genetics and Evolution, vol.1, issue.3, pp.201-205, 2002.
DOI : 10.1016/S1567-1348(02)00027-8

K. Mantelingu, B. A. Reddy, V. Swaminathan, A. H. Kishore, N. B. Siddappa et al., Specific Inhibition of p300-HAT Alters Global Gene Expression and Represses HIV Replication, Chemistry & Biology, vol.14, issue.6, pp.645-657, 2007.
DOI : 10.1016/j.chembiol.2007.04.011

U. Mbonye and J. Karn, Transcriptional control of HIV latency: Cellular signaling pathways, epigenetics, happenstance and the hope for a cure, this issue, 2014.
DOI : 10.1016/j.virol.2014.02.008

D. Mcmahon, J. Jones, A. Wiegand, S. J. Gange, M. Kearney et al., Short???Course Raltegravir Intensification Does Not Reduce Persistent Low???Level Viremia in Patients with HIV???1 Suppression during Receipt of Combination Antiretroviral Therapy, Clinical Infectious Diseases, vol.50, issue.6, pp.912-919, 2010.
DOI : 10.1086/650749

S. A. Migueles, M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. Marincola et al., HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors, Proceedings of the National Academy of Sciences, vol.375, issue.6532, pp.2709-2714, 2000.
DOI : 10.1038/375606a0

S. Moir, C. M. Buckner, J. Ho, W. Wang, J. Chen et al., B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy, Blood, vol.116, issue.25, pp.5571-5579, 2010.
DOI : 10.1182/blood-2010-05-285528

G. Mousseau, M. A. Clementz, W. N. Bakeman, N. Nagarsheth, M. Cameron et al., An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription, Cell Host & Microbe, vol.12, issue.1, pp.97-108, 2012.
DOI : 10.1016/j.chom.2012.05.016

S. M. Murray, C. M. Down, D. R. Boulware, W. M. Stauffer, W. P. Cavert et al., Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection, Journal of Virology, vol.84, issue.22, pp.12082-12086, 2010.
DOI : 10.1128/JVI.01466-10

V. Narayan, K. C. Ravindra, C. Chiaro, D. Cary, B. B. Aggarwal et al., Celastrol Inhibits Tat-Mediated Human Immunodeficiency Virus (HIV) Transcription and Replication, Journal of Molecular Biology, vol.410, issue.5, pp.972-983, 2011.
DOI : 10.1016/j.jmb.2011.04.013
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140654

E. Negredo, M. Massanella, M. C. Puertas, M. J. Buzon, J. Puig et al., Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy, Journal of Antimicrobial Chemotherapy, vol.68, issue.10, pp.2358-2362, 2013.
DOI : 10.1093/jac/dkt183

N. Noel, F. Boufassa, C. Lecuroux, A. Saez-cirion, C. Bourgeois et al., Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients, AIDS, vol.28, issue.4, pp.467-476, 2014.
DOI : 10.1097/QAD.0000000000000174
URL : https://hal.archives-ouvertes.fr/pasteur-01420524

C. L. Novis, N. M. Archin, M. J. Buzon, E. Verdin, J. L. Round et al., Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation, Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation, p.119, 2013.
DOI : 10.1128/JCM.41.10.4531-4536.2003

G. M. Ortiz, D. F. Nixon, A. Trkola, J. Binley, X. Jin et al., HIV-1???specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy, Journal of Clinical Investigation, vol.104, issue.6, pp.13-18, 1999.
DOI : 10.1172/JCI7371

B. J. Osborne, P. M. Sheth, T. J. Yi, C. Kovacs, E. Benko et al., Impact of Antiretroviral Therapy Duration and Intensification on Isolated Shedding of HIV-1 RNA in Semen, The Journal of Infectious Diseases, vol.207, issue.8, pp.1226-1234, 2013.
DOI : 10.1093/infdis/jit026

A. Oxenius, D. A. Price, P. J. Easterbrook, C. A. O-'callaghan, A. D. Kelleher et al., Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes, Proceedings of the National Academy of Sciences, vol.5, issue.5, pp.3382-3387, 2000.
DOI : 10.1038/8400

S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. J. Hanna et al., Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy, Proceedings of the National Academy of Sciences, vol.188, issue.8, pp.3879-3884, 2008.
DOI : 10.1016/j.mbs.2003.08.003

N. I. Paton, R. L. Goodall, D. T. Dunn, S. Franzen, Y. Collaco-moraes et al., Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy, JAMA, vol.308, issue.4, pp.353-361, 2012.
DOI : 10.1001/jama.2012.6936

F. Pereyra, M. M. Addo, D. E. Kaufmann, Y. Liu, T. Miura et al., Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy, The Journal of Infectious Diseases, vol.197, issue.4, pp.563-571, 2008.
DOI : 10.1086/526786

O. Connor, D. H. Ojikutu, B. O. Okulicz, J. Oladehin, O. O. Oldfield et al., The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Science, vol.330, pp.1551-1557, 2010.

E. E. Perez, J. Wang, J. C. Miller, Y. Jouvenot, K. A. Kim et al., Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases, Nature Biotechnology, vol.73, issue.7, pp.808-816, 2008.
DOI : 10.1038/nbt1410

M. Perez, A. G. De-vinuesa, G. Sanchez-duffhues, N. Marquez, M. L. Bellido et al., Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency, Current HIV Research, vol.8, issue.6, pp.418-429, 2010.
DOI : 10.2174/157016210793499312

D. Persaud, H. Gay, C. Ziemniak, Y. H. Chen, M. Piatak et al., Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant, New England Journal of Medicine, vol.369, issue.19, pp.1828-1835, 2013.
DOI : 10.1056/NEJMoa1302976

C. W. Peterson, P. Younan, K. R. Jerome, and H. P. Kiem, Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART, Gene Therapy, vol.52, issue.7, pp.695-702, 2013.
DOI : 10.1038/mt.2008.200

T. A. Peterson, J. Kimani, C. Wachihi, T. Bielawny, L. Mendoza et al., HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort, Tissue Antigens, vol.17, issue.2, pp.93-107, 2013.
DOI : 10.1111/tan.12051

S. K. Pillai, M. Abdel-mohsen, J. Guatelli, M. Skasko, A. Monto et al., Role of retroviral restriction factors in the interferon-??-mediated suppression of HIV-1 in vivo, Proceedings of the National Academy of Sciences, vol.21, issue.19, pp.3035-3040, 2012.
DOI : 10.1093/bioinformatics/bti607

A. Pires, G. Hardy, B. Gazzard, F. Gotch, and N. Imami, Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.36, issue.3, pp.783-790, 2004.
DOI : 10.1097/00126334-200407010-00004

F. Porichis and D. E. Kaufmann, Role of PD-1 in HIV Pathogenesis and as Target for Therapy, Current HIV/AIDS Reports, vol.182, issue.1, pp.81-90, 2012.
DOI : 10.1007/s11904-011-0106-4

J. M. Prins, S. Jurriaans, R. M. Van-praag, H. Blaak, R. Van-rij et al., Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy, AIDS, vol.13, issue.17, pp.2405-2410, 1999.
DOI : 10.1097/00002030-199912030-00012

B. Ramratnam, R. Ribeiro, T. He, C. Chung, V. Simon et al., Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.1, pp.33-37, 2004.
DOI : 10.1097/00126334-200401010-00004

T. A. Rasmussen, O. Schmeltz-sogaard, C. Brinkmann, F. Wightman, S. R. Lewin et al., Comparison of HDAC inhibitors in clinical development, Human Vaccines & Immunotherapeutics, vol.15, issue.5, pp.993-1001, 2013.
DOI : 10.1186/1742-4690-8-80

S. Resino, A. Perez, E. Seoane, D. Serrano, J. Berenguer et al., Short Communication: Immune Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in HIV-Infected Patients: Might Be Better Than Expected?, AIDS Research and Human Retroviruses, vol.23, issue.4, pp.543-548, 2007.
DOI : 10.1089/aid.2006.0071

S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J. S. Gatot et al., Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection, PLoS ONE, vol.4, issue.6, p.6093, 2009.
DOI : 10.1371/journal.pone.0006093.s008
URL : https://hal.archives-ouvertes.fr/hal-00464770

L. Reynolds, C. Ullman, M. Moore, M. Isalan, M. J. West et al., Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors, Proceedings of the National Academy of Sciences, vol.295, issue.5556, pp.1615-1620, 2003.
DOI : 10.1126/science.1067081

E. S. Rosenberg, M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes et al., Immune control of HIV-1 after early treatment of acute infection, Nature, vol.407, pp.523-526, 2000.

J. P. Routy, C. L. Tremblay, J. B. Angel, B. Trottier, D. Rouleau et al., Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study, HIV Medicine, vol.15, issue.5, pp.291-296, 2012.
DOI : 10.1111/j.1468-1293.2011.00975.x

J. Roy, J. S. Paquette, J. F. Fortin, and M. J. Tremblay, The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication, Antimicrobial Agents and Chemotherapy, vol.46, issue.11, pp.3447-3455, 2002.
DOI : 10.1128/AAC.46.11.3447-3455.2002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC128699

S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Foca et al., Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial, PLoS ONE, vol.6, issue.11, p.80157, 2013.
DOI : 10.1371/journal.pone.0080157.s004

A. Saez-cirion, C. Bacchus, L. Hocqueloux, V. Avettand-fenoel, I. Girault et al., Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study, PLoS Pathog, vol.9, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01420534

A. Saez-cirion and G. Pancino, HIV controllers: a genetically determined or inducible phenotype?, Immunological Reviews, vol.473, issue.1, pp.281-294, 2013.
DOI : 10.1111/imr.12076
URL : https://hal.archives-ouvertes.fr/pasteur-01420535

N. Sagot-lerolle, A. Lamine, M. L. Chaix, F. Boufassa, J. P. Aboulker et al., Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir, AIDS, vol.22, issue.10, pp.1125-1129, 2008.
DOI : 10.1097/QAD.0b013e3282fd6ddc

M. Salgado, S. A. Rabi, K. A. O-'connell, R. W. Buckheit, J. R. Bailey et al., Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy, Retrovirology, vol.8, issue.1, p.97, 2011.
DOI : 10.1186/1742-4690-8-97

H. M. Sarau, J. A. Rush, J. J. Foley, M. E. Brawner, D. B. Schmidt et al., Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function, J Pharmacol Exp Ther, vol.283, pp.411-418, 1997.

I. Sarkar, I. Hauber, J. Hauber, and F. Buchholz, HIV-1 Proviral DNA Excision Using an Evolved Recombinase, Science, vol.280, issue.5371, pp.1912-1915, 2007.
DOI : 10.1126/science.280.5371.1880

A. Savarino, A. Mai, S. Norelli, S. Daker, S. Valente et al., "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence, Retrovirology, vol.6, issue.1, p.52, 2009.
DOI : 10.1186/1742-4690-6-52

T. Schacker, New tools to track HIV, Nature Medicine, vol.358, issue.4, pp.373-374, 2010.
DOI : 10.1038/nm0410-373

L. Shan, K. Deng, N. S. Shroff, C. M. Durand, S. A. Rabi et al., Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation, Immunity, vol.36, issue.3, pp.491-501, 2012.
DOI : 10.1016/j.immuni.2012.01.014

I. L. Shytaj, B. Chirullo, W. Wagner, M. G. Ferrari, R. Sgarbanti et al., Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS, Retrovirology, vol.10, issue.1, p.71, 2013.
DOI : 10.1126/scitranslmed.3001628

C. Simonelli, S. Zanussi, C. Pratesi, M. Rupolo, R. Talamini et al., Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV???Infected versus HIV???Uninfected Patients with Relapsed or Refractory Lymphoma, Clinical Infectious Diseases, vol.50, issue.12, pp.1672-1679, 2010.
DOI : 10.1086/652866

F. Sora, A. Antinori, N. Piccirillo, A. De-luca, P. Chiusolo et al., Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia, Experimental Hematology, vol.30, issue.3, pp.279-284, 2002.
DOI : 10.1016/S0301-472X(01)00793-7

A. Steel, S. Clark, I. Teo, S. Shaunak, M. Nelson et al., No change to HIV-1 latency with valproate therapy, AIDS, vol.20, issue.12, pp.1681-1682, 2006.
DOI : 10.1097/01.aids.0000238421.36313.fa

R. Steingrover, K. Pogany, F. Garcia, E. Jurriaans, S. Brinkman et al., HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy, AIDS, vol.22, issue.13, pp.1583-1588, 2008.
DOI : 10.1097/QAD.0b013e328305bd77

W. Stohr, S. Fidler, M. Mcclure, J. Weber, D. Cooper et al., Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy, PLoS ONE, vol.56, issue.10, p.78287, 2013.
DOI : 10.1371/journal.pone.0078287.s001

E. Van-gulck, L. Heyndrickx, L. Bracke, S. Coppens, E. Florence et al., Control of viral replication after cessation of HAART, OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective longlasting CD4+ T cell depletion, pp.218-226, 2001.
DOI : 10.1159/000023949

C. Vandergeeten, R. Fromentin, S. Dafonseca, M. B. Lawani, I. Sereti et al., Interleukin-7 promotes HIV persistence during antiretroviral therapy, Blood, vol.121, issue.21, pp.4321-4329, 2013.
DOI : 10.1182/blood-2012-11-465625
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663425

G. Vanham and E. Van-gulck, Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 9, p.72, 2012.
DOI : 10.1186/1742-4690-9-72
URL : http://doi.org/10.1186/1742-4690-9-72

V. Velu, K. Titanji, B. Zhu, S. Husain, A. Pladevega et al., Enhancing SIV-specific immunity in vivo by PD-1 blockade, Nature, vol.369, issue.7235, pp.206-210, 2009.
DOI : 10.1038/nature07662
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753387

P. Volberding, L. Demeter, R. J. Bosch, E. Aga, C. Pettinelli et al., Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment, AIDS, vol.23, issue.15, 1987.
DOI : 10.1097/QAD.0b013e32832eb285

T. J. Wilkin, C. M. Lalama, J. Mckinnon, R. T. Gandhi, N. Lin et al., A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256, Journal of Infectious Diseases, vol.206, issue.4, pp.534-542, 2012.
DOI : 10.1093/infdis/jis376

T. J. Wilkin, H. R. Ribaudo, A. R. Tenorio, and R. M. Gulick, The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients, HIV Clinical Trials, vol.46, issue.6, pp.351-358, 2010.
DOI : 10.1086/504693

F. W. Wit, D. H. Blanckenberg, K. Brinkman, J. M. Prins, M. E. Van-der-ende et al., Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study, Aids, vol.19, pp.345-348, 2005.

V. Wyl, S. Gianella, M. Fischer, B. Niederoest, H. Kuster et al., Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption, PLoS One, vol.6, 2011.

Z. Yang, N. He, and Q. Zhou, Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression, Molecular and Cellular Biology, vol.28, issue.3, pp.967-976, 2008.
DOI : 10.1128/MCB.01020-07
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223388

P. M. Younan, P. Polacino, J. P. Kowalski, C. W. Peterson, N. J. Maurice et al., Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model, Blood, vol.122, issue.2, pp.179-187, 2013.
DOI : 10.1182/blood-2013-01-482224

S. A. Yukl, A. K. Shergill, K. Mcquaid, S. Gianella, H. Lampiris et al., Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy, AIDS, vol.24, issue.16, pp.2451-2460, 2010.
DOI : 10.1097/QAD.0b013e32833ef7bb

C. Zala, H. Salomon, C. Ochoa, G. Kijak, A. Federico et al., Higher Rate of Toxicity With No Increased Efficacy When Hydroxyurea Is Added to a Regimen of Stavudine Plus Didanosine and Nevirapine in Primary HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.4, pp.368-373, 2002.
DOI : 10.1097/00126334-200204010-00007

H. S. Zhang, Z. Ruan, and W. W. Sang, HDAC1/NF??B pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation, Journal of Cellular Physiology, vol.110, issue.12, pp.3385-3391, 2011.
DOI : 10.1002/jcp.22691